Skip to content

Main Menu

Company
Products and Pipeline
Investors
Careers
News
Contact Us

Main Menu

Company
Products and Pipelines
Investors
Careers
News
Contact Us

MEDIA

Latest News

Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings, as well as financial technology services for aesthetic practices.

Main Menu

News
Press Release

21 September 2022

Revance to Participate in the Guggenheim Nantucket Therapeutics Conference

19 September 2022

Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal

19 September 2022

Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY® (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal

15 September 2022

Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)

15 September 2022

Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY® (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)

15 September 2022

Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

« Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Next »

Company

About
PRODUCTS AND PIPELINE
Leadership Team
Board
Partnerships
Contact Us
Sustainability
Medical Educational Grants
Investigator Sponsored Trials

Investors

Investor Relations
Financials And Filings
Corporate Governance
Analyst coverage
FAQ
Press Releases

Careers

Opportunities
Culture
Benefits
Privacy Notice

Media

News

Company

ABOUT
PRODUCTS AND PIPELINE
LEADERSHIP TEAM
BOARD
PARTNERSHIPS
CONTACT US
Sustainability
Medical Educational Grants
Investigator Sponsored Trials

Investors

INVESTOR RELATIONS
FINANCIALS & FILINGS
CORPORATE GOVERNANCE
ANALYST COVERAGE
STOCK INFORMATION
FAQ
PRESS RELEASES

Careers

OPPORTUNITIES
CULTURE
BENEFITS

Media

NEWS

Facebook-f Instagram Twitter Linkedin-in

For customer service, product information, new accounts or adverse events call: 877-3REV-NOW

1222 Demonbreun St
20th Floor
Nashville, TN 37203

©2023 REVANCE AESTHETICS. REVANCE THERAPEUTICS AND THE REVANCE LOGO ARE REGISTERED TRADEMARKS OF REVANCE. DAXI - 003290.2

Social Media Community Guidelines
Privacy Policy
Terms of Use

Social Media Community Guidelines
Privacy Policy
Terms of Use